Drug
Meglumine Antimoniate clinical trials
Also written Glucantime.
How studies write it
Studies that test it under each name
Brand
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2011 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 11
University of Brasilia (3) · Tehran University of Medical Sciences (2) · Oswaldo Cruz Foundation (2) · Combined Military Hospital, Pakistan (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Centro Internacional de Entrenamiento e Investigaciones Médicas (1) · Centro de Investigaciones Bioclínicas de la Fundación Fader (1)
Often tested with
Tested in the same studies.
Allopurinol (2) · Miltefosine (2) · Amphotericin B, deoxycholate drug combination (1) · Amphotericin B (1) · Liposomal amphotericin B (1)
Studies
Open first, then newest update. How each study uses Meglumine Antimoniate is read from its arms, and is right about nine times in ten.
Testing it · 11
- Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)CompletedPhase 3Tehran University of Medical SciencesNCT04340128Written as Meglumine antimoniate
- Low Antimonial Dosage in American Mucosal LeishmaniasisStatus unknownPhase 2/3Oswaldo Cruz FoundationNCT01301937Written as Meglumine antimoniate
- Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous LeishmaniasisCompletedPhase 2/3Oswaldo Cruz FoundationNCT01301924Written as Meglumine antimoniate
- Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in BrazilTerminatedPhase 4University of BrasiliaNCT01310738Written as Antimoniate of N-methylglucamine
- Efficacy of Topical Liposomal Form of Drugs in Cutaneous LeishmaniasisCompletedEarly Phase 1Tehran University of Medical SciencesNCT01050777Written as Liposomal meglumine antimoniate (Glucantime)
- Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age PatientsCompletedPhase 4University of BrasiliaNCT00818818Written as Meglumine antimoniate
- Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and AllopurinolCompletedNot applicableCombined Military Hospital, PakistanNCT00480883Written as meglumine antimoniate, allopurinol
- Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in ColombiaStatus unknownPhase 3Centro Internacional de Entrenamiento e Investigaciones MédicasNCT00487253Written as Meglumine antimoniate
- Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous LeishmaniasisCompletedPhase 4University of BrasiliaNCT00317980Written as Meglumine antimoniate
- Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in BoliviaStatus unknownPhase 2Centro de Investigaciones Bioclínicas de la Fundación FaderNCT00537953Written as Miltefosine , meglumine antimoniate
- Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in BrazilCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00004755Written as glucantime
Given in every arm · 3 — Meglumine Antimoniate is usual care beside what is tested
- Comparison of Intralesional Glucantime With and Without Fractional CO₂ Laser in Adults With Cutaneous LeishmaniasisNot yet recruitingPhase 2Combined military hospital PeshawarNCT07652021Written as Meglumine Antimoniate
- The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in BrazilActive, not recruitingPhase 2University of BrasiliaNCT02530697Written as Meglumine antimoniate
- Add-on Study of Pentoxifylline in Cutaneous LeishmaniasisCompletedPhase 2/3Centro Internacional de Entrenamiento e Investigaciones MédicasNCT01464242Written as Meglumine antimonate
As the comparator · 10 — what is tested is compared with Meglumine Antimoniate
- Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New WorldCompletedPhase 3Drugs for Neglected DiseasesNCT04515186Written as Meglumine Antimoniate
- Miltefosine and GM-CSF in Cutaneous LeishmaniasisCompletedPhase 3Hospital Universitário Professor Edgard SantosNCT03023111Written as Sbv
- Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis PatientsStatus unknownPhase 2Infan Industria Quimica Farmaceutica NacionalNCT03084952Written as Glucantime
- Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.CompletedPhase 3Universidad de AntioquiaNCT00471705Written as Glucantime®
- Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous LeishmaniasisCompletedPhase 2Hospital Universitário Professor Edgard SantosNCT03294161Written as Meglumine antimoniate
- Amphotericin B to Treat Visceral Leishmaniasis in Brazilian ChildrenCompletedPhase 4University of BrasiliaNCT01032187Written as Meglumine antimoniate
- High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and ManausTerminatedPhase 3Hospital Universitário Professor Edgard SantosNCT01953744Written as Meglumine Antimoniate
- Safety and Efficacy of Azithromycin to Treat Cutaneous LeishmaniasisTerminatedPhase 2/3Ana RabelloNCT00682656Written as Glucantime®
- Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous LeishmaniasisTerminatedPhase 3Fundación Cardiovascular de ColombiaNCT00317629Written as meglumine antimoniate
- Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous LeishmaniasisCompletedPhase 2Hospital Universitário Professor Edgard SantosNCT00973128Written as Meglumine antimoniate
Codes
What other systems call Meglumine Antimoniate · ClinicalTrials.gg INT006734
- MeSH (NLM) D000077485Meglumine AntimoniateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 75G4TW236WMEGLUMINE ANTIMONIATEConfirmed FDA, NLM, Wikidata
- RxNorm 319866Confirmed FDA, Wikidata
- Wikidata Q2757969meglumine antimoniateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C219213Meglumine AntimoniateOne source FDA
- DrugBank DB13732One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077485 | Meglumine Antimoniate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 75G4TW236W | MEGLUMINE ANTIMONIATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 319866 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2757969 | meglumine antimoniate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C219213 | Meglumine Antimoniate | One source FDA |
| DrugBank | DB13732 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.